The American cannabis industry looks very different in 2026 from the expansion-at-any-cost market that defined the early years of state legalization. The largest operators are now being judged less by how many licenses they can accumulate and more by whether they can turn those licenses into profitable stores, recognizable brands, sustainable cultivation operations, and positive cash flow. Price compression remains intense in mature states, competition continues to increase, and regulatory differences between states still prevent cannabis from functioning like an ordinary national consumer-goods industry. At the same time, federal movement of marijuana to Schedule III during 2026 has dramatically changed the financial discussion surrounding medical cannabis businesses, particularly by reducing the burden associated with Internal Revenue Code Section 280E for qualifying operations.
The companies standing out in 2026 therefore represent several different strategies. Curaleaf and Green Thumb Industries have enormous national footprints. Trulieve remains extraordinarily powerful in Florida while becoming more visible in conventional U.S. capital markets. Verano and Cresco Labs have built large retail and consumer-brand platforms. Vireo Growth has emerged as the industry’s most aggressive consolidator, while Ascend Wellness, TerrAscend, Jushi, and Glass House Brands demonstrate that focused regional strategies can still compete with the biggest multistate operators. The following list considers revenue, retail presence, brands, cultivation, financial performance, growth strategy, and overall influence rather than treating market capitalization or a single quarter’s sales as the only measure of success.
1. Curaleaf
Curaleaf remains one of the largest cannabis companies operating from the United States and arguably the broadest cannabis platform on this list. The company generated approximately $340 million in revenue during the second quarter of 2026, including nearly $289 million from its domestic business. Curaleaf’s U.S. operations combine a massive retail network with cultivation, manufacturing, wholesale distribution, and nationally recognized product brands. By the second half of the year, its operated and managed dispensary footprint had grown to roughly 175 locations, with Florida alone accounting for more than 70 stores.
What separates Curaleaf from most American competitors is its international strategy. While the majority of U.S. multistate operators remain almost entirely dependent on state-regulated American markets, Curaleaf has spent years developing businesses in Europe, including Germany and other emerging medical cannabis markets. International revenue exceeded $50 million in the second quarter of 2026. That gives Curaleaf a potential advantage if European medical markets expand rapidly, although operating internationally also adds complexity. With extensive retail distribution, Select products, flower brands, medical operations, and European exposure, Curaleaf enters the end of 2026 as one of the few cannabis companies capable of credibly describing itself as both a U.S. leader and a global cannabis business.
2. Green Thumb Industries
Green Thumb Industries has increasingly distinguished itself by combining national scale with financial discipline. The Chicago-based company generated approximately $307 million in second-quarter 2026 revenue, up from the previous year, while reporting positive GAAP net income and maintaining nearly $284 million in cash. Its Normalized EBITDA exceeded $84 million for the quarter. Those figures are particularly significant in an industry where many large competitors spent years generating substantial sales without consistently demonstrating bottom-line profitability.
Green Thumb’s consumer business includes RYTHM, Dogwalkers, Good Green, Doctor Solomon’s and other brands, supported by its RISE dispensary chain. By late 2026, RISE had grown beyond 120 stores across 14 U.S. markets, with continued expansion in Florida, Pennsylvania, Nevada, and New Jersey. Green Thumb is also positioned for the planned launch of adult-use cannabis sales in Virginia in 2027, where it already operates medical infrastructure. Its ability to invest while maintaining a comparatively strong balance sheet has made Green Thumb one of the industry’s benchmark operators. In 2026, being large is no longer unusual; being large, liquid, cash-generative, and operationally disciplined is considerably more valuable.
3. Trulieve Cannabis
Trulieve remains one of America’s most formidable cannabis operators because of the depth of its position in Florida. The company built its early dominance through a vertically integrated medical cannabis system that allowed it to control cultivation, manufacturing, distribution, and retail. That strategy turned Trulieve into the leading dispensary operator in Florida while subsequent acquisitions expanded its presence into additional states. Even after structural changes to its portfolio in 2026, the company generated approximately $271 million in second-quarter revenue with an unusually high 60 percent gross margin.
The bigger story in 2026 is Trulieve’s movement into mainstream U.S. capital markets. The company became the first state-licensed U.S. cannabis operator of its kind to list on the New York Stock Exchange, trading under the symbol TRLV, and subsequently redomiciled from British Columbia to Delaware. Those developments would have been difficult to imagine during the years when major American cannabis operators were largely confined to Canadian exchanges and over-the-counter markets. Trulieve also generated substantial operating and free cash flow during the first half of 2026. Its concentration in Florida remains both its greatest strength and an important exposure, but few U.S. cannabis businesses have demonstrated comparable ability to dominate a single major state market.
4. Vireo Growth
No company changed its position in the U.S. cannabis hierarchy more dramatically during 2026 than Vireo Growth. Once a comparatively modest regional operator, Vireo has pursued an aggressive consolidation strategy involving a rapid succession of acquisitions. During the second quarter alone, reported revenue reached approximately $209 million, more than quadrupling from the prior-year quarter as newly acquired operations were integrated. On a pro forma basis reflecting additional transactions, quarterly revenue was estimated at roughly $255 million.
Vireo’s acquisition campaign has included businesses and assets associated with Eaze, Proper, Deep Roots, Wholesome, PharmaCann, Hawthorne, Bridgewell and additional operators, while the company has also announced transactions involving FLUENT, C21, selected Cannabist assets, Planet 13, and other state-level operations. If all announced deals are completed, Vireo expects a footprint approaching 270 dispensaries across approximately 16 states, potentially making it the largest U.S. cannabis operator by store count. Execution will determine whether this strategy ultimately succeeds. Integrating dozens of businesses, systems, brands, cultivation facilities, and regulatory structures is enormously difficult. Nevertheless, Vireo is unquestionably one of the defining cannabis companies of 2026 because it has revived large-scale consolidation at a time when much of the industry had shifted toward caution.
5. Verano Holdings
Verano remains one of the largest vertically integrated cannabis companies in the United States, supported by a broad retail network and strong positions in several high-value markets. The company generated approximately $218 million in second-quarter 2026 revenue, representing both sequential and year-over-year growth. Adjusted EBITDA exceeded $51 million, and operating cash flow remained positive. That combination gives Verano meaningful scale without depending entirely on rapid acquisitions for growth.
Its retail operations are best known through the Zen Leaf and MÜV dispensary brands, while its product portfolio spans flower, concentrates, edibles, vapes, and wellness products. Verano has historically emphasized states with limited-license structures, where regulatory barriers can protect established operators from unrestricted competition. Florida, Illinois, New Jersey, Pennsylvania, Maryland, and other markets have all contributed to the company’s national importance. In an industry increasingly focused on extracting more productivity from existing assets, Verano’s vertically integrated infrastructure and established consumer reach continue to make it one of America’s most important cannabis platforms.
6. Cresco Labs
Cresco Labs built its reputation by approaching marijuana more like a consumer packaged goods business than a collection of disconnected cultivation licenses. The Chicago company operates the Sunnyside dispensary chain while distributing brands such as Cresco, High Supply, FloraCal and Mindy’s across major state markets. Second-quarter 2026 revenue reached approximately $173 million, with adjusted EBITDA around $40 million and adjusted gross margin above 50 percent.
Cresco’s wholesale capabilities have long distinguished it from competitors that rely heavily on sales through their own dispensaries. Building brands that can sell through third-party retailers is important if cannabis eventually begins resembling traditional alcohol or consumer-goods markets, where manufacturers do not necessarily own every store carrying their products. The company has also spent recent years simplifying its operations and emphasizing markets where it sees stronger long-term economics. Cresco may no longer be pursuing the kind of headline-grabbing megamerger that dominated cannabis speculation several years ago, but its brands, distribution expertise, and Sunnyside retail network keep it firmly among the leading U.S. companies.
7. Ascend Wellness Holdings
Ascend Wellness Holdings has steadily grown into one of the more important mid-sized multistate operators. Rather than attempting to cover every legal cannabis market, Ascend has concentrated on selected states where it believes retail density and vertically integrated production can produce attractive economics. Its second-quarter 2026 net revenue reached approximately $126 million, up almost 8 percent sequentially, while adjusted EBITDA climbed above $29 million.
Retail is particularly important to the Ascend model. The company expanded to roughly 55 owned and partner locations during the first half of 2026, with growing exposure to markets including Ohio, New Jersey, Illinois, Massachusetts, Pennsylvania, and Michigan. Ascend has also focused increasingly on selling its own branded products through its stores, allowing it to capture value at both the production and retail stages. With operating cash flow and free cash flow improving during 2026, Ascend demonstrates how a cannabis operator can continue expanding without matching Curaleaf or Green Thumb store for store.
8. TerrAscend
TerrAscend is smaller by revenue than the industry’s largest multistate operators, but its financial consistency earns it a place among the strongest U.S. cannabis companies of 2026. Following its decision to treat Michigan operations as discontinued, the company’s continuing business generated approximately $67 million in second-quarter net revenue. More importantly, gross margin reached 54 percent and adjusted EBITDA margin exceeded 26 percent.
The company has built particularly meaningful positions in Pennsylvania, New Jersey and Maryland while operating brands and dispensaries tailored to those markets. TerrAscend entered the second half of 2026 with 16 consecutive quarters of positive operating cash flow from continuing operations and 12 consecutive quarters of positive free cash flow. That record stands out in cannabis, where rapid expansion historically consumed cash faster than many companies could generate it. TerrAscend illustrates an important 2026 theme: investors, operators, and industry observers increasingly care more about the quality of revenue and cash generation than simply having the largest geographical map.
9. Jushi Holdings
Jushi Holdings has quietly developed a valuable portfolio centered on markets where regulatory barriers limit the number of licensed operators. Second-quarter 2026 revenue reached approximately $71 million, representing about 10 percent year-over-year growth, while wholesale revenue rose sharply. The company’s Beyond Hello dispensaries provide its primary retail identity, supported by vertically integrated cultivation and manufacturing operations.
Virginia is particularly important to Jushi’s future. The company already has an established medical cannabis position there and reported record quarterly revenue in the state during 2026. With Virginia authorizing adult-use sales beginning in 2027, existing operators possessing cultivation facilities, dispensaries, patient relationships, and regulatory experience could have a meaningful head start. Jushi therefore represents a different kind of growth opportunity than companies racing to accumulate dozens of new states. Its value lies in holding strong positions in selected markets before those markets reach their full potential.
10. Glass House Brands
Glass House Brands approaches the cannabis business differently from the typical multistate operator. Rather than building its identity around dozens of dispensaries across many states, the California company has focused heavily on enormous greenhouse cultivation capacity. Its Southern California facilities are designed to produce cannabis at agricultural scale using natural sunlight supplemented by sophisticated environmental controls, creating one of the largest legal cannabis cultivation platforms in the country.
During the second quarter of 2026, Glass House produced roughly 246,000 pounds of cannabis biomass and reported wholesale biomass revenue of more than $41 million. The company expects annual production approaching one million pounds, illustrating the extraordinary scale of its agricultural model. Glass House also became listed on the New York Stock Exchange in 2026 and has positioned itself around the possibility that future federal reforms could eventually permit broader interstate cannabis commerce or exports. California remains one of America’s most challenging cannabis markets because of taxation, regulation, illicit-market competition, and wholesale price volatility, but Glass House’s extremely low-cost greenhouse strategy makes it one of the most distinctive companies preparing for a potentially more open national market.
How Schedule III Is Reshaping the Largest Cannabis Companies
Federal cannabis policy became one of the defining business developments of 2026. The move of marijuana to Schedule III significantly altered the tax environment surrounding state-legal medical cannabis activities. For years, Internal Revenue Code Section 280E prevented businesses trafficking in Schedule I or Schedule II controlled substances from deducting ordinary business expenses in the same way as conventional companies. The result was an extraordinary tax burden that could leave cannabis operators owing substantial federal income taxes despite modest actual profits.
The largest operators are among the biggest potential beneficiaries because they historically paid some of the industry’s largest 280E tax bills. Schedule III does not create nationwide recreational legalization, eliminate state licensing systems, automatically authorize interstate cannabis commerce, or transform dispensaries into ordinary pharmacies. It does, however, change financial assumptions that have shaped the industry for more than a decade. Companies with strong existing operations, manageable debt, recognized brands, and positive cash flow may now be better positioned to invest, reduce debt, or expand than competitors that survived primarily through repeated capital raises.
The U.S. Cannabis Companies Best Positioned for the Next Phase
Curaleaf currently offers perhaps the broadest combination of U.S. scale and international exposure, while Green Thumb remains one of the industry’s strongest examples of disciplined national growth. Trulieve continues to dominate one of America’s largest medical markets and has broken important capital-market barriers. Verano and Cresco remain established national platforms, while Ascend, TerrAscend, and Jushi demonstrate the value of focused regional execution. Glass House provides a radically different large-scale cultivation model.
Vireo Growth is the wildcard. If its extraordinary acquisition campaign is successfully completed and integrated, the company could emerge from 2026 with the largest retail footprint in American cannabis and revenue capable of placing it among the industry’s biggest operators. If integration proves difficult, its rapid expansion could become an example of the risks that caused the previous cannabis consolidation cycle to unravel.
The most important lesson from 2026 is that the definition of a “top cannabis company” has matured. Store count and revenue still matter, but they are no longer enough. The companies most likely to shape the next phase of American cannabis will need efficient cultivation, trusted brands, strong retail execution, access to capital, positive cash flow, regulatory expertise, and the financial durability to survive continuing price competition. The industry is moving out of its speculative adolescence. Its next leaders will be determined less by who builds the biggest empire on paper and more by who can turn legal cannabis into a sustainable national business.
